Conformational Selectivity of ITK Inhibitors: Insights from Molecular Dynamics Simulations

Overview

Journal J Chem Inf Model

Publisher American Chemical Society

Specialties Chemistry
Medical Informatics

Date 2023 Dec 9

PMID 38069816

Authors

Naoki Ogawa

Masateru Ohta

Mitsunori Ikeguchi

Affiliations

Soon will be listed here.

Abstract

Interleukin-2-inducible T-cell kinase (ITK) regulates the response to T-cell receptor signaling and is a drug target for inflammatory and immunological diseases. Molecules that bind preferentially to the active form of ITK have low selectivity between kinases, whereas those that bind preferentially to the inactive form have high selectivity for ITK. Therefore, computational methods to predict the conformational selectivity of compounds are required to design highly selective ITK inhibitors. In this study, we performed absolute binding free-energy perturbation (ABFEP) simulations for 11 compounds on both active and inactive forms of ITK, and the calculated binding free energies were compared with experimental data. The conformational selectivity of 10 of the 11 compounds was correctly predicted using ABFEP. To investigate the mechanism underlying the stabilization of the active and inactive structures by the compounds, we performed extensive, conventional molecular dynamics simulations, which revealed that the compound-induced stabilization of the P-loop and linkage of conformational changes in L489, V419, F501, and M410 upon compound binding were critical factors. A guideline for designing inactive-form binders is proposed based on these key structural factors. The ABFEP and the created guidelines are expected to facilitate the discovery of highly selective ITK inhibitors.

References

Manning G, Whyte D, Martinez R, Hunter T, Sudarsanam S . The protein kinase complement of the human genome. Science. 2002; 298(5600):1912-34. DOI: 10.1126/science.1075762. View

Pastor R, Burch J, Magnuson S, Ortwine D, Chen Y, De La Torre K . Discovery and optimization of indazoles as potent and selective interleukin-2 inducible T cell kinase (ITK) inhibitors. Bioorg Med Chem Lett. 2014; 24(11):2448-52. DOI: 10.1016/j.bmcl.2014.04.023. View

Moriarty K, Takahashi H, Pullen S, Khine H, Sallati R, Raymond E . Discovery, SAR and X-ray structure of 1H-benzimidazole-5-carboxylic acid cyclohexyl-methyl-amides as inhibitors of inducible T-cell kinase (Itk). Bioorg Med Chem Lett. 2008; 18(20):5545-9. DOI: 10.1016/j.bmcl.2008.09.015. View

Lu C, Wu C, Ghoreishi D, Chen W, Wang L, Damm W . OPLS4: Improving Force Field Accuracy on Challenging Regimes of Chemical Space. J Chem Theory Comput. 2021; 17(7):4291-4300. DOI: 10.1021/acs.jctc.1c00302. View

Winters M, Robinson D, Khine H, Pullen S, Woska Jr J, Raymond E . 5-Aminomethyl-1H-benzimidazoles as orally active inhibitors of inducible T-cell kinase (Itk). Bioorg Med Chem Lett. 2008; 18(20):5541-4. DOI: 10.1016/j.bmcl.2008.09.016. View

Weeks S, Harris R, Karimi M . Targeting ITK signaling for T cell-mediated diseases. iScience. 2021; 24(8):102842. PMC: 8326193. DOI: 10.1016/j.isci.2021.102842. View

Andreotti A, Schwartzberg P, Joseph R, Berg L . T-cell signaling regulated by the Tec family kinase, Itk. Cold Spring Harb Perspect Biol. 2010; 2(7):a002287. PMC: 2890196. DOI: 10.1101/cshperspect.a002287. View

Burch J, Barrett K, Chen Y, Devoss J, Eigenbrot C, Goldsmith R . Tetrahydroindazoles as Interleukin-2 Inducible T-Cell Kinase Inhibitors. Part II. Second-Generation Analogues with Enhanced Potency, Selectivity, and Pharmacodynamic Modulation in Vivo. J Med Chem. 2015; 58(9):3806-16. DOI: 10.1021/jm501998m. View

Lin T, McIntyre K, Das J, Liu C, ODay K, Penhallow B . Selective Itk inhibitors block T-cell activation and murine lung inflammation. Biochemistry. 2004; 43(34):11056-62. DOI: 10.1021/bi049428r. View

10.

Abdel-Magid A . Dual Inhibition of IL-2-Inducible T-Cell Kinase (ITK) and Tropomyosin Receptor Kinase A (TRKA) as Potential Treatment for Atopic Dermatitis and Other Inflammatory and Autoimmune Diseases. ACS Med Chem Lett. 2021; 12(12):1889-1891. PMC: 8667067. DOI: 10.1021/acsmedchemlett.1c00619. View

11.

Trani G, Barker J, Bromidge S, Brookfield F, Burch J, Chen Y . Design, synthesis and structure-activity relationships of a novel class of sulfonylpyridine inhibitors of Interleukin-2 inducible T-cell kinase (ITK). Bioorg Med Chem Lett. 2014; 24(24):5818-5823. DOI: 10.1016/j.bmcl.2014.10.020. View

12.

Kutach A, Villasenor A, Lam D, Belunis C, Janson C, Lok S . Crystal structures of IL-2-inducible T cell kinase complexed with inhibitors: insights into rational drug design and activity regulation. Chem Biol Drug Des. 2010; 76(2):154-63. DOI: 10.1111/j.1747-0285.2010.00993.x. View

13.

MacKinnon C, Lau K, Burch J, Chen Y, Dines J, Ding X . Structure-based design and synthesis of potent benzothiazole inhibitors of interleukin-2 inducible T cell kinase (ITK). Bioorg Med Chem Lett. 2013; 23(23):6331-5. DOI: 10.1016/j.bmcl.2013.09.069. View

14.

Valley C, Cembran A, Perlmutter J, Lewis A, Labello N, Gao J . The methionine-aromatic motif plays a unique role in stabilizing protein structure. J Biol Chem. 2012; 287(42):34979-34991. PMC: 3471747. DOI: 10.1074/jbc.M112.374504. View

15.

Chen W, Cui D, Jerome S, Michino M, Lenselink E, Huggins D . Enhancing Hit Discovery in Virtual Screening through Absolute Protein-Ligand Binding Free-Energy Calculations. J Chem Inf Model. 2023; 63(10):3171-3185. DOI: 10.1021/acs.jcim.3c00013. View

16.

Mao C, Zhou M, Uckun F . Crystal structure of Bruton's tyrosine kinase domain suggests a novel pathway for activation and provides insights into the molecular basis of X-linked agammaglobulinemia. J Biol Chem. 2001; 276(44):41435-43. DOI: 10.1074/jbc.M104828200. View

17.

Wang L, Friesner R, Berne B . Replica exchange with solute scaling: a more efficient version of replica exchange with solute tempering (REST2). J Phys Chem B. 2011; 115(30):9431-8. PMC: 3172817. DOI: 10.1021/jp204407d. View

18.

Blass B . Covalent Inhibitors of the TEC Family of Kinases and Their Methods of Use. ACS Med Chem Lett. 2018; 9(7):587-589. PMC: 6047041. DOI: 10.1021/acsmedchemlett.8b00178. View

19.

Moriarty K, Winters M, Qiao L, Ryan D, DesJarlis R, Robinson D . Itk kinase inhibitors: initial efforts to improve the metabolical stability and the cell activity of the benzimidazole lead. Bioorg Med Chem Lett. 2008; 18(20):5537-40. DOI: 10.1016/j.bmcl.2008.09.017. View

20.

Hantani Y, Iio K, Hantani R, Umetani K, Sato T, Young T . Identification of inactive conformation-selective interleukin-2-inducible T-cell kinase (ITK) inhibitors based on second-harmonic generation. FEBS Open Bio. 2018; 8(9):1412-1423. PMC: 6120236. DOI: 10.1002/2211-5463.12489. View